Articles from ResMed Inc.

Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com

SAN DIEGO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2025 on Thursday, January 30, 2025, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.

SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, beginning at approximately 3:00 p.m. (Pacific Standard Time) in San Francisco, CA.

SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, Chairman and Chief Executive Officer, and Dr. Carlos Nunez, Chief Medical Officer, will participate in a fireside chat at the UBS Global Healthcare Conference on Tuesday, November 12, 2024, beginning at approximately 3:30 p.m. (Pacific Standard Time) at the Terranea Resort Hotel in Rancho Palos Verdes, CA.

Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com

SAN DIEGO, Oct. 03, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2025 on Thursday, October 24, 2024, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.

NEW YORK and SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today unveiled its 2030 Strategy to drive growth, profitability, and shareholder returns at an Investor Day in New York City. ResMed also announced its five-year revenue and earnings growth outlook, reflecting ResMed’s plans to accelerate product and technology innovation, operational excellence, commercial execution, and financial strength. Driven by the new strategy, ResMed expects to help more than 500 million people worldwide achieve their full health potential in 2030.

SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD), the world’s leading health technology company focused on sleep, breathing, and care delivered in the home, today announced new patient-centric products designed to enhance the therapy journey for sleep apnea patients. These innovations integrate with digital wearable devices and generative artificial intelligence designed to deliver a more personalized sleep health experience and improve overall health.

The new AirTouch™ N30i tube-up nasal mask for CPAP combines softness, breathability, and a high-performance, durable seal to provide exceptional comfort

The new AirTouch™ N30i tube-up nasal mask for CPAP combines softness, breathability, and a high-performance, durable seal to provide exceptional comfort

SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD), the world’s leading health technology company focused on sleep, breathing, and care delivered in the home, today announced new patient-centric products designed to enhance the therapy journey for sleep apnea patients. These innovations integrate with digital wearable devices and generative artificial intelligence designed to deliver a more personalized sleep health experience and improve overall health.

SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) will host an investor day on Monday, September 30, 2024, beginning at approximately 1:00 p.m. (Eastern Daylight Time). As previously announced, the event will be held at the New York Stock Exchange in New York City and simultaneously webcast online.

New ResMed-supported research presented at ERS 2024 projects future Chronic Obstructive Pulmonary Disease (COPD) burden in Western Europe, accounting for increased air pollution, tobacco smoking, and vaping, with Non-Invasive Ventilation (NIV) enhancing survival rates.

SAN DIEGO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, Chairman and Chief Executive Officer, and Dr. Carlos Nunez, Chief Medical Officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024, beginning at approximately 10:00 a.m. (Eastern Daylight Time) at the New York Marriott Marquis in New York, NY.

SAN DIEGO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it has expanded the size of its board of directors to 11 and has elected Christopher DelOrefice to the board, effective immediately. Mr. DelOrefice was appointed during ResMed’s regularly scheduled board meeting on August 15, 2024, and will stand for re-election with the rest of ResMed’s directors at its annual meeting on November 21, 2024. Mr. DelOrefice has also been appointed as a member of ResMed’s board audit committee.

Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com

SAN DIEGO, July 03, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2024 on Thursday, August 1, 2024, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.

ResMed studies presented at SLEEP 2024 also revealed a 17% prevalence of insomnia among adults in North America, Latin America, and the Caribbean, and a higher rate of depression in women with OSA

Among 26 ResMed-supported abstracts, these were the highlights:

SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) --

SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Dr. Carlos Nunez, Chief Medical Officer, and Amy Wakeham, Chief Investor Relations Officer, will participate in a fireside chat at the 2024 RBCCM Global Healthcare Conference on Tuesday, May 14, 2024, beginning at approximately 4:05 p.m. (Eastern Daylight Time) at the InterContinental New York Barclay, in New York, NY.

Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com

SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2024 on Thursday, April 25, 2024, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.

SAN DIEGO, March 15, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD), the global leader in digital health and cloud-connected medical devices that transform care for people with sleep apnea, COPD, and other chronic diseases, today announced the results of its 2024 Global Sleep Survey in conjunction with World Sleep Day (March 15), shedding light on the critical sleep challenges faced by people around the world.

SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD), a global leader in digital health and cloud-connected medical devices that transform care for people with sleep apnea and other chronic respiratory diseases, today announced the U.S. launch of the AirFit F40, an ultra-compact, full-face mask offering the comfort of smaller masks without sacrificing performance in order to help improve sleep apnea therapy compliance.2

SAN DIEGO, Feb. 12, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) launched today its AirCurve 11 series devices, the company’s newest bilevel devices that use two levels of support, inspiratory positive airway pressure (IPAP) and expiratory positive airway pressure (EPAP), combined with digital technology to make it easier for healthcare providers to treat sleep apnea and to help patients start and stay on therapy. AirCurve 11 devices are built on ResMed’s market-leading AirSense 11 platform and enhance the suite of offerings available for healthcare providers and clinicians when determining the best care for sleep apnea patients.

Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com

SAN DIEGO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2024 on Wednesday, January 24, 2024, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.

SAN DIEGO, Dec. 27, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chief executive officer and chair of the board, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, beginning at approximately 2:15 p.m. (Pacific Standard Time) at the Westin St. Francis in San Francisco, CA.

ResMed’s masks with magnets are safe when used in accordance with the updated Instructions for Use

SAN DIEGO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) announced that it has secured a significant victory after the United States Patent Trial and Appeals Board (PTAB) invalidated the claims New York University (NYU) asserted against ResMed, based on seven NYU patents.

SAN DIEGO, Dec. 07, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced the results of a study on the global burden of Chronic Obstructive Pulmonary Disease (COPD) through 2050. Published in the Journal of the American Medical Association (JAMA) Network Open, the study found that COPD prevalence among those 25 years and older is expected to increase by 23% from 2020 to 2050, with the largest growth projected among women and within low- and middle-income countries.

SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced a new operating model to accelerate long-term growth. The new operating model introduces dedicated leadership in Product, Revenue, and Marketing to the global executive team. This change aims to increase the velocity of product development and sharpen our customer and brand focus. Ultimately, the goal is to accelerate profitable growth, while driving greater value and improved care throughout the outside hospital care continuum and the patient journey.

Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com

SAN DIEGO, Oct. 05, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2024 on Thursday, October 26, 2023, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.

SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced its participation in two upcoming conferences.

Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com

SAN DIEGO, July 06, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2023 on Thursday, August 3, 2023, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.

SAN DIEGO, July 05, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced the acquisition of privately held Somnoware, a U.S. leader in sleep and respiratory care diagnostics software.

INDIANAPOLIS, June 08, 2023 (GLOBE NEWSWIRE) -- People with heart failure and obstructive sleep apnea (OSA) can significantly reduce hospitalizations and ER visits as well as related costs by being adherent on positive airway pressure (PAP) therapy, according to two studies supported by ResMed (NYSE: RMD, ASX: RMD) and presented at SLEEP 2023.

SAN DIEGO, June 05, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Rob Douglas, president and chief operating officer, will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on Monday, June 12, 2023, beginning at approximately 9:20 a.m. (Pacific Daylight Time) at the Waldorf Astoria Monarch Beach in Dana Point, CA.

WASHINGTON, May 25, 2023 (GLOBE NEWSWIRE) -- Renowned medical experts at the American Thoracic Society International Conference unveiled new evidence that demonstrates treating obstructive sleep apnea (OSA) with positive airway pressure (PAP) therapy lowers all-cause mortality for patients. In addition, a late-breaking abstract showed treating central sleep apnea (CSA) caused a “significant and clinically relevant improvement” in their symptoms and quality of life. The studies were among 24 supported by ResMed (NYSE: RMD, ASX: RMD).

SAN DIEGO, May 02, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced the appointment of two new executive team members: Michael Rider, Global General Counsel & Secretary, effective July 1, 2023, and Dawn Haake as ResMed’s first Chief Quality Officer, effective May 1, 2023. Both joined ResMed’s executive team on May 1 and report to the Office of the CEO.

Year-over-year revenue grows 29%, operating profit up 28%, non-GAAP operating profit up 27%

SAN DIEGO, April 06, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2023 on Thursday, April 27, 2023, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.

SAN DIEGO, March 30, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) announced today that David Pendarvis, chief administrative officer, global general counsel, and secretary, plans to retire, effective June 30, 2023. He will remain in a consulting role with ResMed through December 31, 2023.

SAN DIEGO, March 15, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Rob Douglas, president and chief operating officer, will join a fireside chat at the 2023 KeyBanc Life Sciences & MedTech Investor Forum on Tuesday, March 21, 2023, beginning at approximately 3:45 p.m. (Eastern Daylight Time) via webcast.

SAN DIEGO, March 13, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) announced today the results from its 2023 Global Sleep Survey in conjunction with National Sleep Awareness Week (March 12-18) and World Sleep Day (March 17) to raise awareness for the importance of sleep as a key component of physical and mental health.

SAN DIEGO, March 07, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Rob Douglas, president and chief operating officer, will present at the Oppenheimer 33rd Annual Healthcare Conference on Monday, March 13, 2023, beginning at approximately 11:20 a.m. (Eastern Daylight Time) via webcast.

Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com

SAN DIEGO, Jan. 26, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced ResMed’s board of directors has appointed chief executive officer Michael (“Mick”) Farrell as chair of the board, effective January 25, 2023. Mr. Farrell succeeds current chair Peter Farrell who will become chair emeritus and will remain an active board member.

SAN DIEGO, Jan. 12, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2023 on Thursday, January 26, 2023, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.

SAN DIEGO, Jan. 02, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chief executive officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023, beginning at approximately 1:30 p.m. (Pacific Standard Time) at the Westin St. Francis in San Francisco, CA.

-  Acquisition expands ResMed’s SaaS business to Germany, first non-U.S. market

Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com

SAN DIEGO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2023 on Thursday, October 27, 2022, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss these results. Other forward-looking and material information may also be discussed during this webcast.